🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the battle against superbug strains of the infection, according to health experts.

A Worldwide Health Concern

Cases of gonorrhoea are escalating worldwide, with data suggesting more than 82 million infections each year. Particularly high rates are reported in the African continent and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune advancement in the reality of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The WHO has classified it as a "critical concern". A tracking program found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Drugs Gain Clearance

One new antibiotic, alternatively called Nuzolvence, was authorized by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in close succession. This treatment, which is additionally indicated for UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to bring it to fruition.

“This milestone signifies a significant shift in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Results and Global Access

Based on results published in a major medical journal, the new drug successfully treated more than 90% of genital gonorrhoea infections. This places it at an equal footing with the typical regimen, which combines an injection and a pill. The research enrolled nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the rights to license and sell the drug in numerous low-income and middle-income countries.

Clinicians on the front lines have voiced hope. Having a easy-to-administer therapy of this kind is hailed as a "game-changer" for public health efforts. This is considered essential to reduce the burden of the disease for individuals and to prevent the spread of untreatable gonorrhoea worldwide.